<DOC>
	<DOCNO>NCT01981928</DOCNO>
	<brief_summary>The purpose study see safe study drug well tolerate dose . The study also investigate study drug take , metabolize ( chemically break ) , distribute body excrete . A aim look process possibly alter food give study drug presence absence meal .</brief_summary>
	<brief_title>A Clinical Trial Investigate Safety Tolerability ASP7962 Healthy Humans</brief_title>
	<detailed_description />
	<criteria>The subject body mass index ( BMI ) range 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg . [ screen ] Female subject must nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile status post hysterectomy ( least 1 month prior Screening ) . Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout clinical study period 90 day final study drug administration . Male subject must donate sperm start screen throughout clinical study period 90 day final study drug administration . Subject agree participate another interventional study clinical study . Subject know suspected hypersensitivity ASP7962 component formulation used.Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge Medical Investigator . Subject clinically significant abnormality follow Investigator 's review physical examination , ECG clinical study protocoldefined clinical laboratory test screen admission clinical unit day 1 . Subject regularly us inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit day 1 . Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit day 1 . Subject participate interventional clinical study treat investigational drug within 90 day 5 halflives whichever longer , prior initiation screen Subject history suicide attempt suicidal behavior . Any recent suicidal ideation within last 3 month ( level 4 5 1 item scale ) , significant risk commit suicide , judge Investigator use CSSRS screen admission clinical unit day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Single Ascending Oral Dose</keyword>
	<keyword>Food Effect</keyword>
</DOC>